Samuel Isaly’s Orbimed Advisors recently filed a Form 13D with the Securities and Exchange Commission, in which it reported a new stake in Selecta Biosciences Inc (NASDAQ:SELB). The position amasses 1.84 million shares, which account for 10.03% of the outstanding stock of the company. The filing also revealed that this acquisition of shares is solely for investment purposes and that the fund will continue to further examine its investment by monitoring the company’s business moves.
Selecta Biosciences is a clinical-stage biopharmaceutical company that works on discovering therapeutics that could help patients who suffer from a variety of serious and rare conditions. The company recently started trading on the Nasdaq, on June 23, and its shares have remained largely unchanged since then, save for a short downward blip on June 24. The company has a market cap of $250 million.
You can access the original SEC filing by clicking here.
Follow Cartesian Therapeutics Inc.
Follow Cartesian Therapeutics Inc.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
OrbiMed Advisors | 0 | 1,842,797 | 0 | 1,842,797 | 1,842,797 | 10.3% |
OrbiMed Capital GP III | 0 | 1,825,415 | 0 | 1,825,415 | 1,825,415 | 10.2% |
Samuel D. Isaly | 0 | 1,842,797 | 0 | 1,842,797 | 1,842,797 | 10.3% |
Follow Samuel Isaly's OrbiMed Advisors
Page 1 of 13 – SEC Filing
SELECTA BIOSCIENCES, INC.
COMMON STOCK
816212104
Telephone: (212) 739-6400
June 27, 2016